Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer

AZD3409 is an orally active double prodrug that was developed as a novel dual prenyltransferase inhibitor. The formation of the active metabolite AZD3409 acid is mediated by esterases in plasma and cells. The aim of this phase I study was to determine the maximum tolerated dose, toxicities, pharmaco...

Descripción completa

Detalles Bibliográficos
Autores principales: Appels, N M G M, Bolijn, M J, Chan, K, Stephens, T C, Hoctin-Boes, G, Middleton, M, Beijnen, J H, de Bono, J S, Harris, A L, Schellens, J H M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2441954/
https://www.ncbi.nlm.nih.gov/pubmed/18506143
http://dx.doi.org/10.1038/sj.bjc.6604402

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2441954/
https://www.ncbi.nlm.nih.gov/pubmed/18506143
http://dx.doi.org/10.1038/sj.bjc.6604402

Ejemplares similares